STOCKHOLM, September 23, 2026 - Moberg Pharma AB (OMX: MOB) announces that as of today our local partner Padagis Israel Agencies Ltd. medical representatives have officially started promoting Terclara® to dermatologists across Israel. The launch follows regulatory clearance by the Israeli Ministry of Health (MOH) of the first commercial batch.
Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara®.
"We are very pleased to see Terclara® launched in Israel and to reach another important milestone in the international commercialization of our product. Padagis has made extensive preparations for the launch, and we look forward to supporting them as Terclara® is introduced to dermatologists and patients in Israel," says Anna Ljung, CEO of Moberg Pharma.
For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se
About this information
The information was released for public distribution through the contact named above, on September 23th, 2026, at 2:45 pm CEST.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 14 countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe, APAC, Canada and China. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).